Dr. Sara Muhammad Ali El-Hanboshy

Lecturer of Pharmacology & Toxicology
Faculty of Pharmacy, Damanhour University

Email: saraalhanboshy@pharm.dmu.edu.eg

Professional Summary

Lecturer of Pharmacology and Toxicology with a research-driven mindset and a strong commitment to advancing cancer therapeutics through innovative pharmaceutical research. Passionate about exploring novel therapeutic strategies and translating molecular discoveries into clinically meaningful applications. My work integrates experimental pharmacology, drug repurposing, and translational oncology to address unmet challenges in cancer treatment. Dedicated to fostering scientific excellence through high-quality teaching, impactful research, interdisciplinary collaboration, and the continuous pursuit of knowledge that contributes to better healthcare and improved patient outcomes.

Education

PhD in Pharmacology & Toxicology, Damanhour University (2022–2026)

Master's degree in pharmacology & Toxicology, Damanhour University (2017–2021)

Bachelor of Pharmaceutical Sciences (Excellent with Honors), Damanhour University (2017)

Academic Experience

Assistant Lecturer, Faculty of Pharmacy, Damanhour University (2022–Present)

Teaching & Research Assistant (Demonstrator) (2017–2021)

Visiting Lecturer of pharmacology, Armed Forces Health Institute (2021–2022)

Teaching Experience

Pharmacology I, II, III | Clinical Pharmacology | Toxicology | Therapeutics | Drug Interactions

Research Expertise

Cancer biology, molecular signaling pathways, cancer immunotherapy, anticancer pharmacology

Cell culture techniques, in vivo cancer models

Publications

1- El-Hanboshy, S.M., Abdel-Raheem, I.T. & Helmy, M.W. Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models. Futur J Pharm Sci 12, 20 (2026). https://doi.org/10.1186/s43094-026-00937-4

2- 2- El-Hanboshy, S.M., Helmy, M.W. & Abd-Alhaseeb, M.M. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways. Mol Biol Rep 48, 7233–7242 (2021). https://doi.org/10.1007/s11033-021-06715-0

Certifications & Training

TOEFL ITP (Score: 630)

Digital Transformation Certificate

Scientific writing & International publishing, AI in research, biostatistics, research ethics, effective presentation skills, technology use in teaching

Skills

Cell culture | Molecular biology | Data analysis | Experimental design

Languages

Arabic (Native) | English (Fluent)